Syndax Pharmaceuticals(SNDX)

Focus: Syndax is a public oncology-focused biotech specializing in tumor phenotype modification with one marketed product (Revumenib) and a robust pipeline of epigenetic and immunotherapy candidates. The company operates from New York with a lean, R&D-driven model.

Oncology Neurology

Profile data last refreshed 9h ago · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Open Jobs

5-3 this month

Stable — net -3 jobs in 30d

6 added, 9 removed. Backfill posture.

Should You Work at Syndax Pharmaceuticals?

AI assessment

Best fit for early-career or mission-driven scientists willing to trade stability for pipeline depth and upside, pending Revumenib Phase 3 readout and capital planning.

Why Work Here

Only 3 open roles across the company signal highly selective hiring—opportunity to join a focused, mission-driven team rather than navigate a large bureaucracy.

Data completeness

5/9 — Partial

Company HealthStrong

Pipeline

Early-stage

50 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$0K

Key Products

REVUFORJ

Not specified in approved indication data

GROWTH16.4yr

Help build intelligence for Syndax Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline & Clinical Trials

Revumenib

Relapsed/Refractory Acute Leukemia

N/A

Clinical Trials (1)

NCT05918913Expanded Access Program for Revumenib

N/A

Entinostat

Metastatic Breast Cancer

Phase 1

Clinical Trials (1)

NCT03473639A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy

Phase 1

Axatilimab

Solid Tumor

Phase 1

Clinical Trials (1)

NCT03238027A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors

Phase 1

Revumenib

Relapsed/Refractory Leukemias

Phase 1

Clinical Trials (3)

NCT07563010Menin-Inhibitor Targeted Maintenance in AML

Phase 2

NCT07734077Revumenib in Patients With Myelofibrosis

Phase 1/2

Revumenib

Refractory Acute Myeloid Leukemia

Phase 1

Clinical Trials (1)

NCT06177067Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Phase 1

Revumenib

Acute Myeloid Leukemia

Phase 1

Clinical Trials (1)

NCT06313437Revumenib in Combination With 7+3 + Midostaurin in AML

Phase 1

Revumenib

Blinatumomab

Phase 1

Clinical Trials (1)

NCT07283640A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia

Phase 1

Entinostat

Breast Cancer

Phase 1

Clinical Trials (1)

NCT03361800Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC

Phase 1

entinostat

Breast Cancer

Phase 1

Clinical Trials (1)

NCT02820961Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer

Phase 1

SNDX-275

Breast Cancer

Phase 1

Clinical Trials (1)

NCT00754312A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer

Phase 1

entinostat

Lung Cancer

Phase 1

Clinical Trials (1)

NCT01594398Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer

Phase 1

Entinostat

Fallopian Tube Cancer

Phase 1

Clinical Trials (1)

NCT03924245Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Phase 1

Revumenib

Acute Leukemia

Phase 1

Clinical Trials (1)

NCT05406817Study of Radiolabeled Revumenib in Adults With Acute Leukemia

Phase 1

Entinostat

Drug Interaction

Phase 1

Clinical Trials (1)

NCT03187015A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects

Phase 1

Entinostat

Neoplasms

Phase 1

entinostat

Volunteers

Phase 1

Clinical Trials (1)

NCT02922933A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects

Phase 1

Entinostat

Pancreas Cancer

Phase 1

Clinical Trials (1)

NCT03760614A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma

Phase 1

Entinostat

Neoplasms

Phase 1

Clinical Trials (1)

NCT02897778Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors

Phase 1

Entinostat

Renal Impairment

Phase 1

Clinical Trials (1)

NCT03192111A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function

Phase 1

Entinostat

Volunteers

Phase 1

Clinical Trials (1)

NCT02922946Study to Determine the Effect of the Timing of a Meal on the Pharmacokinetics of Entinostat

Phase 1

SNDX-5613

Acute Myeloid Leukemias

Phase 1

Clinical Trials (1)

NCT06226571A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

Phase 1

axatilimab

Chronic Graft-versus-host-disease

Phase 1/2

Clinical Trials (1)

NCT03604692A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD

Phase 1/2

Revumenib

Colorectal Cancer

Phase 1/2

Clinical Trials (1)

NCT05731947Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors

Phase 1/2

Atezolizumab

Metastatic Cancer

Phase 1/2

Clinical Trials (1)

NCT03024437Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma

Phase 1/2

Entinostat

Non-Small-Cell Lung Carcinoma

Phase 1/2

Clinical Trials (1)

NCT00602030Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC

Phase 1/2

Entinostat

Breast Cancer

Phase 1/2

Clinical Trials (1)

NCT02708680Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In

Phase 1/2

entinostat

Non-Small Cell Lung Cancer

Phase 1/2

revumenib

Acute Myeloid Leukemia

Phase 1/2

Clinical Trials (1)

NCT04065399A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Phase 1/2

entinostat

Epithelial Ovarian Cancer

Phase 1/2

Clinical Trials (1)

NCT02915523Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer

Phase 1/2

SNDX-5613

Acute Myeloid Leukemia

Phase 1/2

Clinical Trials (1)

NCT05360160A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Phase 1/2

Venetoclax

Acute Myeloid Leukemia

Phase 1/2

Clinical Trials (1)

NCT06284486A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

Phase 1/2

SNDX-6352

Coronavirus

Phase 2

Clinical Trials (1)

NCT04415073A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19

Phase 2

Entinostat

Metastatic Cholangiocarcinoma

Phase 2

Clinical Trials (1)

NCT03250273A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

Phase 2

Fulvestrant

Breast Cancer

Phase 2

Clinical Trials (1)

NCT02115594Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer

Phase 2

Revumenib

Leukemia

Phase 2

Clinical Trials (1)

NCT06229912A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes

Phase 2

Azacitidine

Non-Small Cell Lung Cancer

Phase 2

Clinical Trials (1)

NCT01928576Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.

Phase 2

Axatilimab

Chronic Graft-versus-host-disease

Phase 2

Clinical Trials (1)

NCT04710576A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

Phase 2

entinostat

Breast Cancer

Phase 2

Clinical Trials (1)

NCT00676663Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer

Phase 2

Entinostat

Renal Cell Carcinoma

Phase 2

Clinical Trials (1)

NCT03501381High Dose IL 2 and Entinostat in RCC

Phase 2

Entinostat

Melanoma

Phase 2

Clinical Trials (1)

NCT03765229An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma

Phase 2

entinostat

Estrogen Receptor-negative Breast Cancer

Phase 2

Clinical Trials (1)

NCT01234532Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery

Phase 2

Pembrolizumab

Metastatic Uveal Melanoma

Phase 2

Entinostat

Renal Cell Carcinoma

Phase 2

Clinical Trials (1)

NCT03552380Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma

Phase 2

Entinostat

ER+ Breast Cancer

Phase 2

Clinical Trials (1)

NCT00828854Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing

Phase 2

Durvalumab

Unresectable Intrahepatic Cholangiocarcinoma

Phase 2

Clinical Trials (1)

NCT04301778Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

Phase 2

Axatilimab

Idiopathic Pulmonary Fibrosis

Phase 2

Clinical Trials (1)

NCT06132256MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Phase 2

Pembrolizumab

Bladder Cancer

Phase 2

Entinostat

Non Small Cell Lung Cancer

Phase 2

Clinical Trials (1)

NCT00750698A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib

Phase 2

Entinostat

Lymphoma

Phase 2

Entinostat

Hodgkin's Lymphoma

Phase 2

Clinical Trials (1)

NCT00866333A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma

Phase 2

Interview Prep Quick Facts

Portfolio: 1 approved product, 48 clinical trials

Top TAs: Oncology, Respiratory, Infectious Diseases

SEC Filings: 2 available

Open Roles: 5 active jobs

Portfolio Health

Growth1 (100%)

1 total products

Therapeutic Area Focus

Oncology

1 marketed39 pipeline

Respiratory

2 pipeline

Infectious Diseases

1 pipeline

Nephrology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

R&D Spend

$163M38%

Net Income

-$209M

Cash

Hiring Trend

Stable

Open Roles

Added

-2

Filled/Removed

Based on last 4 crawl cycles

Syndax Pharmaceuticals(SNDX)

Should You Work at Syndax Pharmaceuticals?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (1)

Pipeline & Clinical Trials

Open Jobs (5)

Oncology Account Manager, Los Angeles

Contractor, Medical Strategy & Field Scientific Engagement (Pulmonary/IPF)

Oncology Account Manager – Nashville

Contractor, Clinical Trial Associate

Contractor, Biostatistician

Financials (FY2025)

Hiring Trend